GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) but their most recent incarnations, which consist of both next generation GLP-1s and combinations (Ozempic, Mounjaro, Wegovy, Zepbound), have moved beyond the realm of T2D into the treatment of obesity
Food and Drug Administration (FDA) to treat obesity, expanding their use beyond the original purpose of diabetes management, demand for these drugs is skyrocketing and employers are struggling to weigh the high costs of coverage
However, this compound is known for being an almost perfect antioxidant, due to its ability to combat oxidative stress in the body
From $30/10ml Lipo-C (Cyanocobalamin/MIC/L-Carnitine) Enhanced lipotropic injection adding L-carnitine to cyanocobalamin and MIC for improved energy and fat transport
Although many people have had safe and good results from using these injectables, that is not always the case